Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04546009 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
A Phase 3 study of Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 992
- Enrollment target
- 20
- Study locations
NCT04546009 is a Phase 3 study of Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 992 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT04546009, a Phase 3 study of Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 992 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer.
Conditions Studied
Interventions
- DRUG Letrozole
- DRUG Palbociclib
- DRUG Giredestrant
- DRUG Giredestrant-matched Placebo
- DRUG Letrozole-matched Placebo
Study Locations (20)
California
- Orange Coast Memorial Medical Center - Fountain Valley
- Long Beach Memorial Medical Center - Long Beach
- Kaiser Permanente - San Leandro Medical Center - San Leandro
- Stanford Univ Medical Center - Stanford
- Kaiser Permanente - Walnut Creek - Walnut Creek
Florida
- Florida Cancer Specialists - Fort Myers (Broadway) - Fort Myers
- Memorial Regional Cancer Ctr - Hollywood
- University of Miami - Miami
- SCRI Florida Cancer Specialists North - St. Petersburg
- SCRI Florida Cancer Specialists PAN - Tallahassee
Colorado
- University of Colorado - Aurora
- Rocky Mountain Cancer Center - Denver
Maryland
- Mercy Medical Center - Baltimore
- Maryland Oncology Hematology - Silver Spring
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
New Jersey
- Memorial Sloan Kettering Cancer Center Basking Ridge - Basking Ridge
- Astera Cancer Care East Brunswick - East Brunswick
Hawaii
- Kaiser Permanente - Moanalua Medical Center - Honolulu
Missouri
- HCA Midwest Division - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 992 participants |
| Start Date | 2020-10-09 |
| Est. Completion | 2028-03-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04546009
The ClinicalTrials.gov registry entry for NCT04546009 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 992 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Letrozole is the first listed.
NCT04546009 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT04546009 about?
NCT04546009 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)". This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2...
What is the current status of trial NCT04546009?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 992 participants. The study started on 2020-10-09. Estimated completion is 2028-03-25.
What conditions does trial NCT04546009 study?
This clinical trial studies the following conditions: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer.
What interventions are being tested in trial NCT04546009?
The interventions under investigation include: Letrozole (DRUG), Palbociclib (DRUG), Giredestrant (DRUG), Giredestrant-matched Placebo (DRUG), Letrozole-matched Placebo (DRUG).
Who is sponsoring clinical trial NCT04546009?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04546009 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Hawaii, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.